Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients

Liver International

Volumn 29, Issue 8, 2009, Pages 1178-1183

  Terrault, Norah A ^a   Tran, Tram T ^b   Schiff, Eugene ^c   McGuire, Brendan M ^d   Brown, Robert S ^e   Tupper, Rebecca ^f   Ramanathan, Srini ^f   Enejosa, Jeffrey ^f   Zhong, Lijie ^f   Zong, Jian ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d University of Alabama at Birmingham   (United States)

^e Columbia University College of Physicians and Surgeons ^*  (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

Calcineurin inhibitors; Hepatitis B; Nucleotide analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; TACROLIMUS; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HALF LIFE TIME; HUMAN; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; AGED; DRUG COMBINATION; DRUG INTERACTION; HEPATITIS B; MIDDLE AGED;

ADENINE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HEPATITIS B; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TACROLIMUS; YOUNG ADULT;

EID: 70350061890     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01998.x     Document Type: Article

References (9)

1. Coffin C, Terrault N. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007; 14(Suppl. 1): 37-44.
2. Schiff E, Lai C, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
3. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-8.
4. Nekvindova J, Masek V, Veinlichova A, et al. Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. Xenobiotica 2006; 36: 1165-77.
5. Matal J, Orsag J, Nekvindova J, et al. Experimental approaches to studies on drug metabolism and drug interactions in man: interaction of acyclic nucleoside phosphonates with human liver cytochromes P450 and flavin-containing monooxygenase 3. Neuro Endocrinol Lett 2006; 27(Suppl. 2): 27-30.
6. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.
7. Dumortier J, Le Derf Y, Guillem P, Chevallier P, Boillot O. Favorable outcome of liver transplantation despite a high hepatitis B virus replication: beyond the limits? Transpl Infect Dis 2006; 8: 182-4.
8. Lo CM, Liu CL, Lau GK, et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-13.
9. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol 2007; 21: 191-7.